The short answer
Tirzepatide activates the GIP receptor and produces up to 22.5% weight reduction. Maridebart cafraglutide blocks the same receptor and also produces substantial reduction. Both are paired with GLP-1 agonism, both work, and whether GIPR should be agonised or antagonised for obesity remains unresolved.
Key facts
- GIPR agonist example
- Tirzepatide (with GLP-1 agonism)
- GIPR antagonist example
- Maridebart cafraglutide (MariTide)
- Shared component
- Both include GLP-1 receptor agonism
- Status of the question
- Unresolved, but now tested directly
- First direct comparison
- Davies 2026, in mice (PMID 41287212)
- Leading hypothesis
- Antagonism may improve tolerability
- Key review
- Annu Rev Nutr 2026 (PMID 42166683)
The contradiction
Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, and it produces greater weight reduction than GLP-1 agonism alone. Maridebart cafraglutide is a bispecific molecule that does the opposite at GIPR: a monoclonal antibody that blocks the receptor, conjugated to two GLP-1 agonist peptides. It also produces pronounced dose-dependent weight reduction. So two compounds do opposite things at the same receptor, and both appear to work.
Why this is not simply an error somewhere
It would be tidier if one programme rested on a misreading, but both have clinical data. Tirzepatide is an approved medicine with pivotal trials behind it. The GIPR antagonist approach was reported in Nature Metabolism in 2024 with preclinical and Phase 1 evidence of dose-dependent reduction and an acceptable tolerability profile. A 2026 review in the Annual Review of Nutrition addresses the paradox directly rather than dismissing either side.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Hypothesis one: it is about tolerability, not efficacy
The most discussed explanation is that GIPR antagonism reduces nausea. If blocking GIPR improves tolerability of a co-administered GLP-1 agonist, then more GLP-1 agonism can be delivered before adverse effects force a dose reduction. On that reading the antagonist is not producing weight loss through GIPR at all. It is removing the ceiling on how much GLP-1 signalling a person can tolerate. The weight reduction would still be GLP-1-driven.
Hypothesis two: chronic agonism becomes functional antagonism
Sustained agonism at a G-protein-coupled receptor commonly causes desensitisation and receptor internalisation. If continuous GIPR agonism downregulates the receptor, then long-term agonism and pharmacological blockade could converge on a similar functional state (reduced GIPR signalling) by different routes. This would make the paradox apparent rather than real, but it is a hypothesis rather than a demonstrated mechanism.
Hypothesis three: central and peripheral GIPR do different things
GIP receptors are expressed in adipose tissue, pancreas and brain, including regions relevant to appetite. If the receptor's role differs by tissue, a molecule reaching central receptors could produce an effect opposite to one acting principally in the periphery. Molecule size and blood-brain-barrier penetration then matter as much as whether a compound agonises or antagonises.
What emerging data suggests
Work reported through 2026 supports the notion that GIPR agonism and antagonism can each provide additive weight reduction when combined with a GLP-1 receptor agonist. A 2026 comparison in male mice examined the two approaches head to head metabolically. This does not yet resolve which is preferable in humans, and it is unusual for a field to advance two opposite pharmacologies this far without settling the question.
Why it matters for reading the field
Any confident claim that GIP agonism is the reason tirzepatide outperforms semaglutide should be read carefully. It is consistent with the data and it may well be right, but a competing programme built on the opposite premise is producing results too. The honest position is that adding GIPR engagement to GLP-1 agonism helps, and the direction of that engagement is not settled.
The first direct comparison
Until recently the two strategies had only ever been compared across separate trials of separate compounds in separate populations, a comparison that cannot settle anything. Davies and colleagues published a metabolic comparison of GIPR agonism against GIPR antagonism in male mice in Diabetes, Obesity and Metabolism in February 2026: both directions, one model, matched conditions. It is a rodent study and it does not resolve the human question, but it is the first time the two have been placed side by side rather than inferred across trials.
Quick reference
| Tirzepatide | Maridebart cafraglutide | |
|---|---|---|
| GIPR action | Agonist | Antagonist |
| GLP-1R action | Agonist | Agonist |
| Format | Single peptide | Antibody + 2 peptides |
| Status | Approved | Investigational |
| Outcome | Weight reduction | Weight reduction |
Frequently asked questions
How can blocking and activating the same receptor both work?
That is the open question. Leading explanations are that antagonism improves tolerability so more GLP-1 can be given, that chronic agonism desensitises the receptor into a similar state, or that central and peripheral GIP receptors differ in role.
Does this mean GIP agonism is not why tirzepatide works better?
It means the inference is less secure than it appears. Adding GIPR engagement clearly helps; the direction of that engagement is unresolved.
Is either approach proven superior?
No. Tirzepatide has approval and pivotal data; the antagonist approach has preclinical and early clinical evidence. No head-to-head resolution exists.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedA GIPR antagonist conjugated to GLP-1 analogues. Nature Metabolism 2024 (PMID 38316982)pubmed.ncbi.nlm.nih.gov
- PubMedThe Paradox and Future of GLP-1/GIP Combination Therapies. Annu Rev Nutr 2026 (PMID 42166683)pubmed.ncbi.nlm.nih.gov
- PubMedThe Premise of the Paradox. GIPR agonist and antagonist programmes (PMID 40507574)pubmed.ncbi.nlm.nih.gov
- PubMedGIPR agonism versus antagonism in male mice. Diabetes Obes Metab 2026 (PMID 41287212)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Maridebart Cafraglutide? Antibody Meets PeptideMariTide is a monoclonal antibody blocking the GIP receptor, conjugated to two GLP-1 agonists. An unusual format, and the opposite premise to tirzepatide.
- Lean Mass Loss on GLP-1 Therapy, and the BELIEVE ResultA substantial share of weight lost on GLP-1 therapy is lean mass. The BELIEVE trial cut lean loss from 7.4% to 2.9% by adding bimagrumab to semaglutide.
- What Is Cagrilintide? The Amylin Half of CagriSemaCagrilintide is a long-acting amylin analogue engineered for weekly dosing. Why native amylin could never be a drug, and what the analogue changed.
- What Is Exenatide? From Gila Monster Venom to MedicineExenatide is a synthetic version of exendin-4, found in Gila monster venom. Why a lizard peptide resists DPP-4 when human GLP-1 does not.
- What Is Liraglutide? The Bridge GenerationLiraglutide uses a C16 fatty acid for albumin binding, giving daily dosing. The step between exenatide and semaglutide, and what changed between them.